Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present)

References

• Rall TW, Sutherland EW. Formation of a cyclic adenine ribonucleotide by tissue particles. J Biol Chem. 1958;232:1065–1076.
   PubMed Web of Science ®Google Scholar
• Rall TW, Sutherland EW. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particulates. J Biol Chem. 1958;232:1077–1091.
   PubMed Web of Science ®Google Scholar
• Smith M, Drummond GI, Khorana HG. Cyclic phosphates. IV. Ribonucleotide 3‘,5’-cyclic phosphates. A general method of synthesis and some properties. J Am Chem Soc. 1979;83:698–706.
   Web of Science ®Google Scholar
• Goldberg ND, Walseth TF, Stephenson JH, et al. 18O-labelling of guanosine monophosphate upon hydrolysis of cyclic guanosine 3‘,5’-monophosphate by phosphodiesterase. J Biol Chem. 1980;255:10344–10347.
   PubMed Web of Science ®Google Scholar
• Burgers PMJ, Eckstein F, Hunneman DH, et al. Stereochemistry of hydrolysis of adenosine 3‘,5’-cyclic phosphorodithioate by the cyclic phosphodiesterase from beef heart. J Biol Chem. 1979;254:9959–9961.
   PubMed Web of Science ®Google Scholar
• Maurice DH, Ke H, Ahmad F, et al. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discovery. 2014;13:290–314.
   PubMed Web of Science ®Google Scholar
• Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther. 2006;109:366–398.
   PubMed Web of Science ®Google Scholar
• Beavo JA, Hardman JG, Sutherland EW. Hydrolysis of cyclic guanosine and adenosine 3‘,5’-monophosphates by rat and bovine tissues. J Biol Chem. 1970;245:5649–5655.
   PubMed Web of Science ®Google Scholar
• Le Trong H, Beier N, Sonnenburg WK, et al. Amino acid sequence of the cyclic GMP stimulated cyclic nucleotide phosphodiesterase from bovine heart. Biochemistry. 1990;29:10280–10288.
   PubMed Web of Science ®Google Scholar
• Sonnenburg WK, Mullaney PJ, Beavo JA. Molecular cloning of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase cDNA. Identification and distribution of isozyme variants. J Biol Chem. 1991;266:17655–17661.
   PubMed Web of Science ®Google Scholar
• Yang Q, Paskind M, Bolger G, et al. A novel cyclic GMP stimulated phosphodiesterase from rat brain. Biochem Biophys Res Commun. 1994;205:1850–1858.
   PubMed Web of Science ®Google Scholar
• Rosman GJ, Martins TJ, Sonneburg WK, et al. Isolation and characterization of human cDNAs encoding a cGMP stimulated 3‘,5’-cyclic nucleotide phosphodiesterase. Gene. 1997;191:89–95.
   PubMed Web of Science ®Google Scholar
• Martins TJ, Mumby MC, Beavo JA. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. J Biol Chem. 1982;254:1973–1979.
   Google Scholar
• Martins TJ. Cyclic GMP-stimulated cyclic nucleotide phosphodiesterase: purification from bovine tissues and characterization [ Ph.D. thesis]. University of Washington; 1984:43–64.
   Google Scholar
• Beavo JA, Hardman JG, Sutherland EW. Stimulation of adenine 3‘,5’-monophosphate hydrolysis by guanosine 3‘,5’-monophosphate. J Biol Chem. 1971;246:3841–3846.
   PubMed Web of Science ®Google Scholar
• Erneux C, Couchie D, Dumont JE, et al. Specificity of cyclic GMP activation of a multi-substrate cyclic nucleotide phosphodiesterase from rat liver. Eur J Biochem. 1981;115:503–510.
   PubMedGoogle Scholar
• Stroop SD, Beavo JA. Structure and function studies of the cGMP-stimulated phosphodiesterase. J Biol Chem. 1991;266:23802–23809.
   PubMed Web of Science ®Google Scholar
• Wu AY, Tang X-B, Martinez SE, et al. Molecular determinants for cyclic nucleotide binding to the regulatory domains of phosphodiesterase 2A. J Biol Chem. 2004;279:37928–37938.
   PubMed Web of Science ®Google Scholar
• Pandit J, Forman MD, Fennell KF, et al. Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct. Proc Natl Acad Sci USA. 2009;106:18225–18230.
   PubMed Web of Science ®Google Scholar
• Mehats C, Andersen CB, Filopanti M, et al. Cylic nucleotide phosphodiesterases and their role in endocrine cell signalling. Trends Endocrinol Metab. 2002;13:29–35.
   PubMed Web of Science ®Google Scholar
• Stephenson DT, Coskran TM, Wilhelms MB, et al. Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species. J Histochem Cytocochem. 2009;75:933–949.
   Web of Science ®Google Scholar
• The human protein atlas. [cited 2016 June 6]. Available from: http://www.proteinatlas.org/ENSG00000186642-PDE2A/tissue.
   Google Scholar
• Human proteome map. [cited 2016 June 6]. Available from: http://www.humanproteomemap.org/.
   Google Scholar
• Lakics V, Karran EH, Boess FG. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology. 2010;59:367–374.
   PubMed Web of Science ®Google Scholar
• Reyes-Irisarri E, Herzog Y, Eyal I, et al. Cognitex supplementation of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer’s disease human brains. Eur J Neurosci. 2007;25:3332–3338.
   PubMed Web of Science ®Google Scholar
• Reneerkens OAH, Rutten K, Steinbusch WWM, et al. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology. 2009;202:419–443.
   PubMed Web of Science ®Google Scholar
• Zhang C, Yu Y, Ruan L, et al. The role of phosphodiesterase 2 in the central nervous and peripheral systems. Curr Pharm Des. 2015;21:274–290.
   PubMed Web of Science ®Google Scholar
• Xu Y, Pan J, Chen L, et al. Phosphodiesterase-2 inhibitor reverses corticosterone-induced neurotoxicity and related behavioral changes via cGMP/PKG dependent pathway. J Neuropsychopharmacol. 2013;16:835–847.
   Web of Science ®Google Scholar
• Masood A, Huang Y, Hajjhussein H, et al. Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling. J Pharmacol Exp Ther. 2009;331:690–699.
   PubMed Web of Science ®Google Scholar
• Plummer MS, Cornicelli J, Roark H, et al. Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part I. Transformation of selective phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors. Bioorg Med Chem Lett. 2013;23:3438–3442.
   PubMed Web of Science ®Google Scholar
• Plummer MS, Cornicelli J, Roark H, et al. Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II. Optimization studies and demonstration of in vivo efficacy. Bioorg Med Chem Lett. 2013;23:3443–3447.
   PubMed Web of Science ®Google Scholar
• Mseeh F, Colman RF, Colman RW. Inactivation of platelet PDE2 by and affinity label: 8-[(4-bromo-2,3-dioxobutylthio]cAMP. Thromb Res. 2000;98:395–401.
   PubMed Web of Science ®Google Scholar
• Surapisitchat J, Jeon K-I, Yan C, et al. Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3. Circulation. 2007;101:811–818.
   Web of Science ®Google Scholar
• Zhang Y, Daaka Y. PDE2 promotes angiogenesis through EP4 and PKA Cγ pathway. Blood. 2011;118:5355–5364.
   PubMed Web of Science ®Google Scholar
• Favot L, Keravis T, Lugnier C. Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4. Thromb Haemost. 2004;92:634–645.
   PubMed Web of Science ®Google Scholar
• Wilson D, Tutulan-Cunita A, Jung W, et al. Deletion of the high-affinity cAMP phosphodiesterase encoded by PDE2 affects stress responses and virulence in Candida albicans. Mol Microbiol. 2007;65:841–856.
   PubMed Web of Science ®Google Scholar
• Bayer Aktiengesellschaft, Preparation of imidazotriazinones as phosphodiesetrase II inhibitors. WO 050078. 2002.
   Google Scholar
• Rutten K, Prickaerts J, Hendrix M, et al. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur J Pharm. 2007;558:107–112.
   PubMed Web of Science ®Google Scholar
• Boess FG, Hendrix M, van der Staay F-J, et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology. 2004;47:1081–1092.
   PubMed Web of Science ®Google Scholar
• Prickaerts J, De Vente J, Honig W, et al. A. cGMP, but not cAMP, in rat hippocampus is involved in early stages of object memory consolidation. Eur J Pharmacol. 2002;436:83–87.
   PubMed Web of Science ®Google Scholar
• Rodefer JS, Saland SK, Eckrich SJ. Selective phosphodiesterase inhibitors improve performance on the ED/ID cognitive task in rats. Neuropharmacology. 2012;62:1182–1190.
   PubMed Web of Science ®Google Scholar
• Reneerkens OA, Rutten K, Bollen E, et al. Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801. Behav Brain Res. 2013;236:16–22.
   PubMed Web of Science ®Google Scholar
• Xu Y, Pan J, Sun J, et al. Inhibition of phosphodiesterarse 2 reverses impaired cognition and neuronal remodeling caused by chronic stress. Neurobiol Aging. 2015;36:955–970.
   PubMed Web of Science ®Google Scholar
• Ding L, Zhang C, Masood A, et al. Protective effects of phosphodiesterase 2 inhibitor on depression- and anxiety-like behaviors: involvement of antioxidant and anti-apoptotic mechanisms. Behav Brain Res. 2014;268:150–158.
   PubMed Web of Science ®Google Scholar
• Reneerkens OAH, Sambeth A, Blokland A, et al. PDE2 and PDE10, but not PDE5, inhibition affect auditory information processing in rats. Behav Brain Res. 2013;250:251–256.
   PubMed Web of Science ®Google Scholar
• Zhu J, Yang Q, Dai D, et al. X-ray crystal structure of phosphodiesterase 2 in complex with a highly selective, nanomolar inhibitor reveals a binding-induced pocket important for selectivity. J Am Chem Soc. 2013;135:11708–11711.
   PubMed Web of Science ®Google Scholar
• Altana Pharma AG, Preparation of purin-6-one derivatives for use in pharmaceutical compositions for the treatment of neoangiogenesis related disorders. WO089953. 2004.
   Google Scholar
• Altana Pharma AG, Preparation of triazolophthalazines as PDE2 inhibitors. WO024640. 2006).
   Google Scholar
• Altana Pharma AG, Triazolophthalazines as phosphodiesterase inhibitors. WO072612. 2006.
   Google Scholar
• Altana Pharma AG, Preparation of 6-anilinotriazolophthalazines as PDE2 inhibitors for medical uses. WO072615. 2006.
   Google Scholar
• Neuro3d, Université Louis Pasteur, Centre National de la Recherche Scientifique, Forenap, Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses. W041258. 2004.
   Google Scholar
• Neuro3d, Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof. EP1548011, 2005.
   Google Scholar
• Neuro3d, Benzodiazepine derivatives, their preparation and therapeutic use thereof. EP1749824. 2007.
   Google Scholar
• Pfizer Products Inc., Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors. WO041957. 2005.
   Google Scholar
• Cambers RJ, Abrams K, Garceau NY, et al. A new chemical tool for exploring the physiological function of the PDE2 isozyme. Bioorg Med Chem Lett. 2006;16:307–310.
   PubMed Web of Science ®Google Scholar
• Pfizer Products Inc., Pyrido[2,3-d]pyrimidine-2,4-diamines as PDE 2 inhibitors. WO061497. 2005.
   Google Scholar
• Biotie Therapies GMBH and Wyeth, Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases. WO054260. 2010.
   Google Scholar
• Biotie Therapies GMBH and Wyeth. Triazine derivatives as inhibitors of phosphodiesterases. WO054253. 2010.
   Google Scholar
• Schröder S, Wenzel B, Deuther-Conrad W, et al. Synthesis, 18F-radiolabelling and biological characterization of novel fluoroalkylated triazine derivatives for in vivo imaging of phosphodiesterase 2A in brain via positron emission tomography. Molecules. 2015;20:9591–9615.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International GMBH. [1,2,4]Triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases. WO104293. 2012.
   Google Scholar
• Malamas MS, Stange H, Schindler R, et al. Novel triazines as potent and selective phosphodiesterase 10A inhibitors. Bioorg Med Chem Lett. 2012;22:5876–5884.
   PubMed Web of Science ®Google Scholar
• Verhoest PR, Chapin DS, Corman M, et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem. 2009;52:5188–5196.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International GMBH, 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes. WO019979. 2014.
   Google Scholar
• Dart Neuroscience, LLC, Substituted [l,2,4]triazolo[l,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors. WO164508.2015.
   Google Scholar
• Janssen Pharmaceutica NV, 1-Aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives. WO000924. 2013.
   Google Scholar
• Janssen Pharmaceutica NV, Combinations comprising PDE2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline compounds and PDE10 inhibitors for use in the treatment of neurological or metabolic disorders. WO001314. 2014.
   Google Scholar
• Chappie TA, Humphrey JM, Allen MP, et al. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors. J Med Chem. 2007;50:182–185.
   PubMed Web of Science ®Google Scholar
• Schmidt CJ, Chapin DS, Cianfrogna J, et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther. 2008;325:681–690.
   PubMed Web of Science ®Google Scholar
• Siuciak JA, McCarthy SA, Chapin DS, et al. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology. 2006;51:374–385.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutica NV. Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors. WO051342. 2011.
   Google Scholar
• Janssen Pharmaceutica NV. Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases. WO110545. 2011.
   Google Scholar
• Andrés J-I, Buijnsters P, De Angelis M, et al. Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors. Bioorg Med Chem Lett. 2013;23:785–790.
   PubMed Web of Science ®Google Scholar
• Buijnsters P, De Angelis M, Langlois X, et al. Structure-based design of a potent, selective, and brain penetrating PDE2 inhibitor with demonstrated target engagement. ACS Med Chem Lett. 2014;5:1049–1053.
   PubMed Web of Science ®Google Scholar
• Rombouts FJR, Tresadern G, Buijnsters P, et al. Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as selective, brain penetrant phosphodiesterase 2 (PDE2) inhibitors. ACS Med Chem Lett. 2015;6:282−86.
   PubMed Web of Science ®Google Scholar
• H. Lundbeck A/S. Triazolopyrazine derivatives and their use for treating neurological and psychiatric disorders. WO034755. 2013.
   Google Scholar
• H. Lundbeck A/S. Substituted triazolopyrazines and uses thereof. WO034758. 2013.
   Google Scholar
• H. Lundbeck A/S. Pyridine compounds and uses thereof. WO034761. 2013.
   Google Scholar
• H. Lundbeck A/S. [l,2,4]Triazolo[4,3-A]quinoxalines as dual PDE2/PDE10 inhibitors. WO139983. 2014.
   Google Scholar
• Redrobe JP, Jørgensen M, Christoffersen CT, et al. In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia. Psychopharmacology. 2014;213:3151–3167.
   Web of Science ®Google Scholar
• Redrobe JP, Rasmussen LK, Christoffersen CT, et al. Characterisation of Lu AF33241: a novel, brain-penetrant, dual inhibitor of phosphodiesterase (PDE) 2A and PDE10A. Eur J Pharmacol. 2015;761:79–85.
   PubMed Web of Science ®Google Scholar
• Pfizer Incorporated. Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders. US0214791. 2012.
   Google Scholar
• Zhang L, Villalobos A, Beck EM, et al. Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand. J Med Chem. 2013;56:4568–4579.
   PubMed Web of Science ®Google Scholar
• Helal CJ. Identification of a brain penetrant, highly selective phosphodiesterase 2A inhibitor for the treatment of cognitive impairment associated with schizophrenia (CIAS). Abstract of Papers, 244th ACS National Meeting & Exposition; 2012 Aug 19–23; Philadelphia, PA.
   Google Scholar
• Pfizer Incorporated. Pyrazolo[3,4-d]pyrimidine compounds and their use as PDE2 inhibitors and/or CPY3A4 inhibitors. WO168817. 2012.
   Google Scholar
• Takeda Pharmaceutical Company Limited. Heterocyclic compound. WO010732. 2014.
   Google Scholar